Entero Therapeutics Inc. has completed a major transformation by acquiring GRID AI, shifting its focus from biotechnology to the grid-edge energy technology sector. As a result of the deal, GRID AI shareholders now hold more than 80 percent of Entero's equity on a fully diluted basis and have significant influence on the company's board. This acquisition positions Entero as a public gateway for AI-driven energy solutions at a time when demand for grid resilience is growing rapidly. The company now operates with a streamlined share float of 1.69 million fully diluted shares, enhancing its visibility and responsiveness in the market. The transition marks Entero's move from lengthy biotech development cycles to addressing immediate challenges in energy technology.